How I treat blastic plasmacytoid dendritic cell neoplasm
https://buff.ly/4aSEkid #HowITreat #MyeloidNeoplasia

Hear! Hear!

Here's our latest, led by Drs. Riaz Gillani & Ryan Collins - we studied a type of inherited genetic event (structural variants) + risk of developing certain cancers in kids:
@danafarber.bsky.social @bostonchildrens.bsky.social @broadinstitute.org @science.org

www.science.org/doi/10.1126/...

What is the role of lactate accumulation in tumor growth and metastasis?

@echouchani.bsky.social is using his Emerging Leader Award from The Mark Foundation to find out.

Check out this new feature from @danafarber.bsky.social to learn more about his work!
danafarberimpact.org/2024/12/canc...

Cool new target and biology in AML from Yoke and Peter @vangalenlab.bsky.social. Happy to have seen this story grow.

Our latest work is now available to read on bioRxiv! Very proud of this and its potential implications for patients with acute myeloid leukemia 🩸 🧪 🔬💊 **eIF4A-mediated translation initiation as an AML cell vulnerability that can be co-targeted with BCL-2 inhibition** www.biorxiv.org/content/10.1...

Thrilled to share a wonderful collaboration with Scott Armstrong, Florian Perner & Shellaina Gordon - exciting times ahead!

www.biorxiv.org/content/10.1...

New insights in #AML and #BPDCN care with Shai Shimony @danafarber.bsky.social at #ASH24 🎥

⭐AML-MR mutations drive CPX-351's benefit over 7+3
⭐Machine learning identifies a 3-parameter survival model for BPDCN
⭐Social determinants of health impact survival in AML across ELN risk groups

Here are the top line overall survival (OS) data with the new #BPDCN 3-parameter prognostic model by Shai Shimony from our BPDCN Center: Favorable, 100% 2-year OS; intermediate, 39% OS and median 21.1 months; adverse, 5% OS and median 9.9 months (factors: age, marrow involvement, signaling mut)

Come see a session about clinical outcomes in #BPDCN, including a machine learning model that has generated a clinically useful and simple 3 factor prognostic scoring model for survival in the disease by superstar new faculty member Shai Shimony @danafarber.bsky.social

8 days ago, ASH decided to join Bluesky. 🌤️ So far, we're enjoying fewer distractions & more meaningful connections. 💬 Engaging with our amazing #hematology and #hemeonc communities has never been easier.

We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed

#Hemesky

Venetoclax-bortezomib-dexamethasone for unfit BPDCN from our French colleagues: pubmed.ncbi.nlm.nih.gov/39642332/

We just opened a search for a lab-based faculty position at Dana-Farber @danafarber.bsky.social @harvardmed.bsky.social

Any area of cancer research is fair game and MD, PhD, or MD/PhD are encouraged to apply.
Please spread the word:
www.nejmcareercenter.org/job/829239/l...

How I Treat #BPDCN
@ash-hematology.bsky.social @mkd-bmt.bsky.social #ASH24 #leusm

ashpublications.org/blood/articl...

Not sure if I can handle another platform but will give this a whirl at #ASH2024. See everyone in San Diego.